Safety and efficacy of a novel abluminal groove-filled biodegradablepolymer sirolimus-eluting stent for the treatment of de novo coronarylesions： 12-month results from the TARGET II trial

作     者：Xu Bo Zhao Yelin Yang Yuejin Zhang Ruiyan Li Hui Ma Changsheng Chen Shaoliang 

作者机构：Department of Cardiology Fu Wai Hospital National Center for Cardiovascular Diseases Beijing 100037 China Department of Cardiology Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200025 China Department of Cardiology Daqing Oil Field General HospitalDaqing Heilongjiang 163114 China Department of Cardiology Affiliated Anzhen Hospital of Capital Medical University Beijing 100029 China Department of Cardiology Nanjing First Hospital Nanjing Medical University Nanjing Jiangsu 210006 China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2014年第127卷第6期

页      面：1027-1032页

核心收录：

学科分类：1006[医学-中西医结合] 1002[医学-临床医学] 10[医学] 100602[医学-中西医结合临床] 

基　　金：sponsored by the MicroPort Scientific Corporation  Shanghai  China 

主　　题：5-YEAR FOLLOW-UP ARTERY-DISEASE CLINICAL-EVALUATION RANDOMIZED-TRIALS VESSEL SIZE INTERVENTION EVEROLIMUS OUTCOMES COHORT REVASCULARIZATION 

摘      要：Background In the TARGET I randomized controlled trial, the novel abluminal groove-filled biodegradable polymersirolimus-eluting stent FIREHAWK proved non-inferior to the everolimus-eluting stent in nine-month in-stent late loss insingle de novo coronary lesions. This study was aimed at evaluating clinical safety and effectiveness of FIREHAWK in amoderately complex population （including patients with small vessels, long lesions and multi-vessels）, and at validatingthe ability of the SYNTAX score （SS） to predict clinical outcomes in patients treated with this latest generation drug-elutingstent.